• Non ci sono risultati.

Table 6. PET/CT and PET/MR SUVmeans and SUVmax in the cervical normal muscles.

N/A
N/A
Info
Scarica
Protected

Academic year: 2021

Condividi "Table 6. PET/CT and PET/MR SUVmeans and SUVmax in the cervical normal muscles."

Copied!
1
0
0

Caricamento.... (Visualizza il testo completo ora)

Scarica adesso ( 1 pagine )

Testo completo

(1)

Table 5. Results of the comparison of the calculated maximum and mean SUVs in all lesions, primary and recurrence and lymphnodes.

Lesions N0 SUV Max (Mean±SD) ρ p value p<0.05 SUV Mean (Mean±SD) ρ p value p<0.05

PET/CT PET/MR PET/CT PET/MR

All lesions 55 8.60±4.9 9.4±5.3 0.97 <0.001 <0.001 5.8±3.3 6.4±3.7 0.96 <0.001 <0.001 Primary/Reccurence 19 10.8±3.7 12.2±4.3 0.94 0.001 0.011 7.7±2.8 8.6±3.5 0.93 0.012 0.001

Lymphnodes 36 6.9±4.5 7.7±4.6 0.94 0.001 <0.001 4.6±3.2 5.3±3.1 0.95 <0.001 0.001

Note - ρ (rho) = correlation coefficent Spearman, p=sig Spearman; p= Wilcoxon signed rank test, significant difference at p<0.05

Table 6. PET/CT and PET/MR SUVmeans and SUVmax in the cervical normal muscles.

Note-Values are means±SD, ρ (rho) = correlation coefficent Spearman, p = sig Spearman;

p=Wilcoxon signed rank test, significant difference at p<0.05

Lesions N0 SUV Max (Mean±SD) ρ p Value p<0.05 SUV Mean (Mean±SD) ρ p Value p<0.05

PET/CT PET/MR PET/CT PET/MR

Riferimenti

Scarica adesso ( PDF - 1 pagine - 253.53 KB )

Documenti correlati

14 Artefacts and Normal Variants in Whole-Body PET and PET/CT Imaging

18 FDG because of competition with glucose [3], al- though it appears that chronic hyperglycaemia, as seen in diabetic patients, only minimally reduces tumour uptake [4].. To

Basic Science of PET and PET/CT 1

The development of the first PET/CT prototype was initi- ated in 1992 with the objectives to integrate CT and PET within the same device, to use the CT images for the atten- uation

PET and PET/CT Imaging in Head and Neck Cancer 8

2[F]-Fluoro-2- deoxy-D-glucose positron emission tomography is a sensitive tool for the detection of occult primary cancer (carcinoma of unknown primary syndrome) with head and

PET and PET/CT Imaging in Lymphoma 9

1. The role of Ga-67 scintigraphy in evaluating the results of therapy of lymphoma patients. Kostakoglu L, Leonard JP, Kuji I, et al. Comparison of fluorine-18 fluorodeoxyglucose

PET and PET/CT Imaging in Colorectal Cancer 10

Clinical as- sessment of positron emission tomography for the diagnosis of local recurrence in colorectal cancer.. Kim CK, Gupta NC, Chandramouli B,

PET and PET/CT Imaging in Esophageal and Gastric Cancers 11

(13) studied 35 patients with esophageal cancer and demonstrated that FDG-PET had a sensitivity of 88% (7/8) and specificity of 93% (25/27) for detection of distant metastatic

PET and PET/CT Imaging in Tumors of the Pancreas andLiver 12

addition of FDG-PET imaging to CT altered the surgical management in 41% of the patients, 27% by detecting CT- occult pancreatic carcinoma and 14% by identifying un- suspected

PET and PET/CT Imaging in Breast Cancer 13

A prospective evaluation of positron emission tomography scanning, sentinel lymph node biopsy, and standard axillary dis- section for axillary staging in patients with early